CA2358505C - Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules - Google Patents
Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules Download PDFInfo
- Publication number
- CA2358505C CA2358505C CA2358505A CA2358505A CA2358505C CA 2358505 C CA2358505 C CA 2358505C CA 2358505 A CA2358505 A CA 2358505A CA 2358505 A CA2358505 A CA 2358505A CA 2358505 C CA2358505 C CA 2358505C
- Authority
- CA
- Canada
- Prior art keywords
- lipid
- biologically relevant
- polymer
- suspension
- cochleates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/829—Liposomes, e.g. encapsulation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
Abstract
A process for producing a small-sized, lipid-based cochleate is described. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca2+ or Zn2+, forms a cochleate precipitate of a particle size less than one micron. The process may be used to produce cochleates containing biologically relevant molecules. Small-sized cochleates may be administered orally or through the mucosa to obtain an effective method of treatment.
Description
NOVEL HYOROGEL ISOLATED COCHLEATE FORMULATIONS, PROCESS OF PREPARATION AND
THEIR USE FOR THE
DELIVERY OF BIOLOGICALLY RELEVANT MOLECULES
1ZELEVANT MOLk:CULES
1'IELD OF THE INVEN'I'lON
The present invention relates to a novel process for preparin-, a novel lipid-based cochleate delivery system, the pllannaceutical preparations derived fi-om the lipid-bascd cochleate delivery system, and the use of these pharmaceutical preparations to achieve efficient systemic and mucosal delivery of biologically relevant molecules.
BACKGROUND OF '1'HU 1NVEN'i'ION
The ability of biologically relevant inolecules to be administered via the oral route depends on several factors. "I'he biologically relevant molecule must be soluble in the gastrointestinal fluids in order Ior the biologicalty relevant molecule to be transported across biological membranes for an active transport mechaiiism, or have suitable sniall particle size that can be absorbed through the Yeyer's Yatclles in the small intestiiie and through the lymphatic system. Particle size is an important parameter when oral delivery is to be achieved (see Couvreur Y. et al, Adv. Drug Delivery Reviews 10:141-1 62, 1993).
The primary issue in the ability to deliver drugs orally is the protection of the drug from proteolytic enzymes. An ideal approach is to incorporate the drug in a hydrophobic material so that the aqueous fluids cannot peiietrate the systecn. Lipid-based cochleates are an ideal system that can achieve this purpose.
The advantages of cochleates are numerous. The cochleates have a nonaqueous structure and therefore they:
a) are more stable because of less oxidation of lipids;
I
b) can be stored lyophilized, which provides the potential to be stored for long periods of time at room lemperatures, which would he advantageous for worldwide shipping and storage prior to administration;
c) maintain their structure even after iyophilization, whereas liposome structures are destroyed by lyophilization;
d) exhibit efficient incorporation of biologically relevant molecules into the lipid bilayer of the cochleate structure;
e) have the potential for slow release of a biologically relevant molecule in vivo as cochleates dissociate;
f) have a lipid bilayer which serves as a carrier and is composed of simple lipids which are found in aninlal and plant cell membranes, so that the lipids are non-toxic;
g) are produced easily and safely;
h) can be produced as defined fornlulations composed of predetermined amounts and ratios of drugs or antigens.
Cochleate structures have been prepared first by D. Papatiadjopoulos as an intermediate in the preparation of large unilamellar vesicles (see US
4,078,052). The use of cochleates to deliver protein or peptide molecules for vaccines has been disclosed in US
5,840,707. However, neither of these patents addresses the importance of particlc size or the effcetive oral delivery of biologically relevant molecules inediated by snlall-sized cochleates.
THEIR USE FOR THE
DELIVERY OF BIOLOGICALLY RELEVANT MOLECULES
1ZELEVANT MOLk:CULES
1'IELD OF THE INVEN'I'lON
The present invention relates to a novel process for preparin-, a novel lipid-based cochleate delivery system, the pllannaceutical preparations derived fi-om the lipid-bascd cochleate delivery system, and the use of these pharmaceutical preparations to achieve efficient systemic and mucosal delivery of biologically relevant molecules.
BACKGROUND OF '1'HU 1NVEN'i'ION
The ability of biologically relevant inolecules to be administered via the oral route depends on several factors. "I'he biologically relevant molecule must be soluble in the gastrointestinal fluids in order Ior the biologicalty relevant molecule to be transported across biological membranes for an active transport mechaiiism, or have suitable sniall particle size that can be absorbed through the Yeyer's Yatclles in the small intestiiie and through the lymphatic system. Particle size is an important parameter when oral delivery is to be achieved (see Couvreur Y. et al, Adv. Drug Delivery Reviews 10:141-1 62, 1993).
The primary issue in the ability to deliver drugs orally is the protection of the drug from proteolytic enzymes. An ideal approach is to incorporate the drug in a hydrophobic material so that the aqueous fluids cannot peiietrate the systecn. Lipid-based cochleates are an ideal system that can achieve this purpose.
The advantages of cochleates are numerous. The cochleates have a nonaqueous structure and therefore they:
a) are more stable because of less oxidation of lipids;
I
b) can be stored lyophilized, which provides the potential to be stored for long periods of time at room lemperatures, which would he advantageous for worldwide shipping and storage prior to administration;
c) maintain their structure even after iyophilization, whereas liposome structures are destroyed by lyophilization;
d) exhibit efficient incorporation of biologically relevant molecules into the lipid bilayer of the cochleate structure;
e) have the potential for slow release of a biologically relevant molecule in vivo as cochleates dissociate;
f) have a lipid bilayer which serves as a carrier and is composed of simple lipids which are found in aninlal and plant cell membranes, so that the lipids are non-toxic;
g) are produced easily and safely;
h) can be produced as defined fornlulations composed of predetermined amounts and ratios of drugs or antigens.
Cochleate structures have been prepared first by D. Papatiadjopoulos as an intermediate in the preparation of large unilamellar vesicles (see US
4,078,052). The use of cochleates to deliver protein or peptide molecules for vaccines has been disclosed in US
5,840,707. However, neither of these patents addresses the importance of particlc size or the effcetive oral delivery of biologically relevant molecules inediated by snlall-sized cochleates.
SUMMARY OF THE INYENTION
Accordingly, it is an object of this invention to provide a niethod for obtaining a hydrogel-isolated cochleate of a particle size less than one micron. '1'he method further comprises the steps required to encoclileate at least one biologically relevant molecule in the hydrogel-isolated cochleates in a therapeutically effective amount.
A "biologically relevant molecule" is one that has a role in the life processes of a living organism. The molecule niay be organic or inorganic, a monomer or a polymer, endogenous to a host organisnl or not, naturally occurring or synthesized in vitro, and the like. Thus, examples include vitamins, minerals, amino acids, toxins, inicrobicides, microbistats, co-factors, enzymes, polypeptides, polypeptide aggregates, polvnucleotides, lipids, carbohydrates, nucleotides, starches, pigments, fatty acids, hormones, cytokines, viruses, organelles, steroids and other multi-ring structures, saccliarides, metals, metabolic poisons, drugs, and the like.
These and other objects llave been obtained by providing an encoclileated biologically relevant molecule, wherein the biologically relevant molecule-cochleate comprises the following components:
a) a biologically relevant molecule, b) a negatively charged lipid, and c) a cation component, wherein the particle size of the encochleated biologically relevant molecule is less than one micron, and further whercin the biologically relevant molecule is preferably a drug.
Accordingly, it is an object of this invention to provide a niethod for obtaining a hydrogel-isolated cochleate of a particle size less than one micron. '1'he method further comprises the steps required to encoclileate at least one biologically relevant molecule in the hydrogel-isolated cochleates in a therapeutically effective amount.
A "biologically relevant molecule" is one that has a role in the life processes of a living organism. The molecule niay be organic or inorganic, a monomer or a polymer, endogenous to a host organisnl or not, naturally occurring or synthesized in vitro, and the like. Thus, examples include vitamins, minerals, amino acids, toxins, inicrobicides, microbistats, co-factors, enzymes, polypeptides, polypeptide aggregates, polvnucleotides, lipids, carbohydrates, nucleotides, starches, pigments, fatty acids, hormones, cytokines, viruses, organelles, steroids and other multi-ring structures, saccliarides, metals, metabolic poisons, drugs, and the like.
These and other objects llave been obtained by providing an encoclileated biologically relevant molecule, wherein the biologically relevant molecule-cochleate comprises the following components:
a) a biologically relevant molecule, b) a negatively charged lipid, and c) a cation component, wherein the particle size of the encochleated biologically relevant molecule is less than one micron, and further whercin the biologically relevant molecule is preferably a drug.
The present invention fi-rthcr providcs a method of orally administering to a host a biologically effective amount of the abovc-describcd cochleate.
In a pi-eferred enibodiment, the biologicallv relevant molecule-cochleate is admiuistered orally.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1. Schematic of the process by which the hydrogel-isolated cochleates with or without drug are obtained.
Figures 2a and 2b. Particle size distribution (weight analysis) of hydrogel isolated cochleates either loaded with amphotericin B (AmB) (fig 2a) or empty (fig 2b) as measured by laser light scattering.
Figures 3a and 3b. Microscopic images of a niixture of liposomes in dextran dispersed into PEG gel solution. The small black dots are dextraii particles formed by dispersing the dextran phase in the PEG phase. 1'he large open circles are formed by fusion of sniall dextran particles. Partition of liposonies favors the dextran phase as indicated by the yellow color of AmB. 3b. Microscopic images of the sample shown in Fig. 3a after treatment with CaCI2 solution. The black objects in circles, indicated by an arrow, are cochleates formed by the addition of Ca2' ions.
Figures 4a-4f. Microscopic images of the sample shown in Figs. 3a and 3b after washing with a buffer containing 1 mM CaClz and 100 mM NaCI. Aggregates are formecl by the Cochleate particles. 4b. Suspension shown in Fig. 4a following the addition of EllTA.
Cochleate particles opened to liposomes with a diameter of 1-2 microns, indicating the intrinsic size of the cochleate particles is in sub-micron range. 4c. AinB hydrogel isolated-cochleates precipitated with zinc according to the procedure described in Example 4. 4d.
Cochleates displayed in fig 4c after treatment with ED"I'A. 4c. Empty hydrogel isolated-cochleates precipitated with zinc according to the procedure described in Example 3. 4f) cochleates displayed in 4f after treatment with ED"1'A.
Figure 5. Micrographs of hydrogel-isolated cochleates after freeze fracture.
Figure 6. Growth inhibition of Candida aibicans by hydrogel-isolated cochleates loaded with AmB at 0.625 g AmB/ml, Comparison is madc to AmB in DMSO and ArnBisomeR.
Figure 7. Effect of hydrogel-isolated cochleates on the viability of Candid albicans after 30 hours.
Figure 8. Efficacy of Amphotericin B-cochleates and macrophage cultures.
Figure 9. Amphotericin B tissue levels after administration of Amphotericin B-cochleates Figure 10. Time profile tissue concentration of AmB after single dose adniinistration of hydrogel-isolated cochleates loaded with AmB.
Figure 11. AmB tissue levcl 24 hrs aftcr single dose and 24 hrs after a multiple dose regime.
Figure 12. Correlation between Amphotericin B tissuc level and the level of Candida albicans after administration of Ainphotcricin B cochleates.
DE1'AILED DESCRIPTION OF THE INVENTION
The present invention provides a solution to achieve effective oral delivery of drugs by producing small-sized cochleates using a new process. The new approach is based on the incompatibility between two polymer solutions, both of which are aqueous.
Aqueous two-phase systems of polymers are well used for protein purification due to a number of advantages such as freedonl froni the need for organic solvents, mild surface tension and the biocompatibility of aqueous polymers (see P.A. Albertsson in "Partition of cell particles and macromolecules", 3"' edition, Wiley NY 1986; and "Separation using aqueous Phase System"
D. Fisher Eds, Plenum NY, 1989). It is known, for- exaniple, that large polar molecules such as proteins partition to a mucli higlier concentration in a polymcr phase with the physical characteristics similar to those of dextran than in a polymer phase with the physical characteristics similar to those of PEG (D. Forciniti, C. K. Ilall, M. R.
Kula, Biotechnol.
Bioeng. 38, 986 1991).
According to the present invention there ar-e provided processes for preparing small-sized, lipid-based cochleate particles and preparations denved therefrom, comprising a biologically relevant molecule incorporated into the particles. The cochleate particles are formed of an alternating sequence of lipid bilayers/cation. The biologically relevant molecule is incorporated either in the lipid bilayers or in the interspace between the lipid bilayers. One of the processes for preparing the small-sized cochleates comprises: 1) preparing a suspension of small unilamellar liposomes or biologically relevant molecule-loaded liposomes, 2) mixing the liposome suspension with polymer A, 3) adding, preferably by injection, the liposome/Polymer A suspension into another polymcr B in which polymer A is nonmiscible, leading to an aqueous two-phase system of polymers, 4) actding a solution of cation salt to the two-phase system of step 3, such that the cation diffuses into polymer B and then into the particles comprised of liposome/polymcr A allowing the formation of small-sized cochleates, 5) washing the polymers out and rcsuspending the empty or drug-loaded cochleates into a physiological buffer or any appropriate pharmaccutical vehicle.
A second process for preparing the small-sized cochleates comprises detergent and a biologically relevant molecule and cation. The process comprises the following steps:
a) providing an aqueous suspension containing a detergent-lipid mixture;
In a pi-eferred enibodiment, the biologicallv relevant molecule-cochleate is admiuistered orally.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1. Schematic of the process by which the hydrogel-isolated cochleates with or without drug are obtained.
Figures 2a and 2b. Particle size distribution (weight analysis) of hydrogel isolated cochleates either loaded with amphotericin B (AmB) (fig 2a) or empty (fig 2b) as measured by laser light scattering.
Figures 3a and 3b. Microscopic images of a niixture of liposomes in dextran dispersed into PEG gel solution. The small black dots are dextraii particles formed by dispersing the dextran phase in the PEG phase. 1'he large open circles are formed by fusion of sniall dextran particles. Partition of liposonies favors the dextran phase as indicated by the yellow color of AmB. 3b. Microscopic images of the sample shown in Fig. 3a after treatment with CaCI2 solution. The black objects in circles, indicated by an arrow, are cochleates formed by the addition of Ca2' ions.
Figures 4a-4f. Microscopic images of the sample shown in Figs. 3a and 3b after washing with a buffer containing 1 mM CaClz and 100 mM NaCI. Aggregates are formecl by the Cochleate particles. 4b. Suspension shown in Fig. 4a following the addition of EllTA.
Cochleate particles opened to liposomes with a diameter of 1-2 microns, indicating the intrinsic size of the cochleate particles is in sub-micron range. 4c. AinB hydrogel isolated-cochleates precipitated with zinc according to the procedure described in Example 4. 4d.
Cochleates displayed in fig 4c after treatment with ED"I'A. 4c. Empty hydrogel isolated-cochleates precipitated with zinc according to the procedure described in Example 3. 4f) cochleates displayed in 4f after treatment with ED"1'A.
Figure 5. Micrographs of hydrogel-isolated cochleates after freeze fracture.
Figure 6. Growth inhibition of Candida aibicans by hydrogel-isolated cochleates loaded with AmB at 0.625 g AmB/ml, Comparison is madc to AmB in DMSO and ArnBisomeR.
Figure 7. Effect of hydrogel-isolated cochleates on the viability of Candid albicans after 30 hours.
Figure 8. Efficacy of Amphotericin B-cochleates and macrophage cultures.
Figure 9. Amphotericin B tissue levels after administration of Amphotericin B-cochleates Figure 10. Time profile tissue concentration of AmB after single dose adniinistration of hydrogel-isolated cochleates loaded with AmB.
Figure 11. AmB tissue levcl 24 hrs aftcr single dose and 24 hrs after a multiple dose regime.
Figure 12. Correlation between Amphotericin B tissuc level and the level of Candida albicans after administration of Ainphotcricin B cochleates.
DE1'AILED DESCRIPTION OF THE INVENTION
The present invention provides a solution to achieve effective oral delivery of drugs by producing small-sized cochleates using a new process. The new approach is based on the incompatibility between two polymer solutions, both of which are aqueous.
Aqueous two-phase systems of polymers are well used for protein purification due to a number of advantages such as freedonl froni the need for organic solvents, mild surface tension and the biocompatibility of aqueous polymers (see P.A. Albertsson in "Partition of cell particles and macromolecules", 3"' edition, Wiley NY 1986; and "Separation using aqueous Phase System"
D. Fisher Eds, Plenum NY, 1989). It is known, for- exaniple, that large polar molecules such as proteins partition to a mucli higlier concentration in a polymcr phase with the physical characteristics similar to those of dextran than in a polymer phase with the physical characteristics similar to those of PEG (D. Forciniti, C. K. Ilall, M. R.
Kula, Biotechnol.
Bioeng. 38, 986 1991).
According to the present invention there ar-e provided processes for preparing small-sized, lipid-based cochleate particles and preparations denved therefrom, comprising a biologically relevant molecule incorporated into the particles. The cochleate particles are formed of an alternating sequence of lipid bilayers/cation. The biologically relevant molecule is incorporated either in the lipid bilayers or in the interspace between the lipid bilayers. One of the processes for preparing the small-sized cochleates comprises: 1) preparing a suspension of small unilamellar liposomes or biologically relevant molecule-loaded liposomes, 2) mixing the liposome suspension with polymer A, 3) adding, preferably by injection, the liposome/Polymer A suspension into another polymcr B in which polymer A is nonmiscible, leading to an aqueous two-phase system of polymers, 4) actding a solution of cation salt to the two-phase system of step 3, such that the cation diffuses into polymer B and then into the particles comprised of liposome/polymcr A allowing the formation of small-sized cochleates, 5) washing the polymers out and rcsuspending the empty or drug-loaded cochleates into a physiological buffer or any appropriate pharmaccutical vehicle.
A second process for preparing the small-sized cochleates comprises detergent and a biologically relevant molecule and cation. The process comprises the following steps:
a) providing an aqueous suspension containing a detergent-lipid mixture;
b) mixing the detergent-lipid suspension witti polymer A;
c) adding the detergent-lipid/polymer A suspension into a solution comprising pol_ymer B, wherein polymer A and polymer B are imrniscible, thereby creatin(; a two-phase polymer system;
d) adding a solution of a cationic moiety to the two-phase polymer system; and e) washing the two-phase polymer systeni to remove the polymer.
A lyopliilization procedure can be applied and the lyophilized biologically relevant molecule-cochleate complex can be filled into soft or hard gelatin capsules, tablets or othcr dosage form, for systemic, dermal or mucosal dclivery.
This process leads to a small-sized particle with a narrow sizc range that allows efficient oral delivery of biologically relevant molecules. 'The biologically relevant molecule partitions into either or both lipid bilayers and interspace, and the biologically relevant molecule is released from the cochlcate particles by dissociation of the particles in vivo.
Alternative routes of administration may bc systemic such as intramuscular, subcutancous or intravenous or mucosal such as intranasal, intraocular, intravaginal, intraanal, parenteral or intrapulmonary. Appropriate dosages arc detenninable by, for example, dose-response experiments in laboratory animals or in clinical trials and taking into account body weight of the patient, absorption rate, half-life, disease severity and the like. The number of doses, daily dosage and course of treatment may vary from individual to individual.
Other delivery routes can be dermal, transdermal or intradennal.
The first step of the new process of the present invention, which is the preparation of small liposomes, can be achieved by standard methods stich as sonication or microfluidization or other related methods (see for example Liposome Tcchnology, Liposome Preparation and Related Techniques, Edited by Gregory Gregoriadis, Vol I, 2nd Edition, CRC Press, 1993).
The addition, preferably by injection, of polymer A/liposome suspension into polymer B can be achieved mechanically by using a syringe pump at an appropriate controlled rate, for example a rate of 0.1 ml/min to 50 ml/min and preferably at a rate of 1 to 10 ml/min.
The lipids of the present invention are non-toxic lipids and include, but are not limited to simple lipids which are found in animal and plant cell membranes.
Preferably the lipid is a negatively charged lipid, more preferably a negatively charged phospholipid, and even more preferably a lipid from the group of phosphatidylserine, phosphatidylinositol, phosphatidic acid, and phosphatidyl glycerol. The lipids may also include minor amounts of zwitterionic lipids, cationic lipids or neutral lipids capable of forming hydrogen bonds to a biologically relevant molecule such as PEGylated lipid.
The polymers A and B of the present invention can be of any biocompatible polymer classes that can produce an aqueous two-phase system. For example, polymer A
can be, but is not limited to, dextran 200,000-500,000, Polyethylene glycol (PEG) 3,400-8,000; polymer B can be, but is not limited to, polyvinylpyrrolidone (PVP), polyvinylalcohol (PVA), FicollT"' 30,000-50,000, polyvinyl methyl ether (PVMB) 60,000-160,000, PEG 3,400-8,000.
The concentration of polymer A can range from between 2-20% w/w as the final concentration depending on the nature of the polymer. The same concentration range can be applied for polymer B. Examples of suitable two-phase systems are Dextran/PEG, 5-20% w/w Dextran 200,000-500,000 in 4-10% w/w PEG 3,400-8,000; Dextran/PVP 10-20% w/w Dextran 200,000-500,000 in 10-20% w/w PVP 10,000-20,000; Dextran/PVA 3-15% w/w Dextran 200,000-500,000 in 3-15% w/w PVA 10,000-60,000; Dextran/FicollT'" 10-20% w/w Dextran 9 PCT/1iS00/01684 200,000-500,000 in 10-20% w/w Ficoll 30,000-50,000; PF,G/PVME 2-10% w/w PEG
3,500-35,000 in 6-15% w/w PVME 60,000-1 60,000.
The biologically rclcvant molecule may be an organic molecule that is hydrophobic in aqueous media. The biologically rclevant molecule may he a drug, and the drug may be an antiviral, an anesthetic, an anti-infeetious, an antifungal, an anticancer, an immunosuppressant, a steroidal anti-inflammatory, a non-steroidal anti-inflammatory, a tranquilizer or a vasodilatory agent. Examples includc Amphotericin B, acyclovir, adriamycin, cabamazepine, melphalan, nifedipine, indomethacin, naproxen, estrogens, testosterones, steroids, phenytoin, ergotamines, cannabinoids raparnycin.
propanidid, propofol, alphadione, echinomycine, miconazole nilrate, teniposide, taxol, and taxotere.
The biologically relevant molecule may be a polypeptide such as cyclosporin, angiotensin 1, 11 and III, enkephalins and their analogs, ACTH, anti-inflarnmatory peptides 1, II, III, bradykinin, calcitonin, b-endorphin, dinorphin, leucokinin, leutinizing hormone releasing hormone (LHRH), insulin, neurokinins, sornatostatin, substance P, thyroid releasing hon none (TRH) and vasopressin.
The biologically relevant molecule may be an antigen, but the antigen is not limited to a protein antigen. The antigen can also be a carbohydrate or a polynucleotide such as DNA.
Examples of antigenic proteins include envelope glycoproteins from influenza or Sendai viruses, animal cell membrane proteins, plant cell membrane proteins, bacterial membrane proteins and parasitic membrane protein.
The biologically rclevant molecule is extracted from the source particle, cell, tissue, or organism by known methods. Biological activity of biologically relevant molecules need not be maintained. However, in some instances (e.g., where a protein has membrane fusion or ligand binding activity or a complex conformation which is recognized by the immune system), it is desirable to maintain the biological activity. In these instances, an extraction buffer containing a detergent which does not destroy the biological activity of the membrane protein is used. Suitable detergents include ionic detergents such as cholate salts, deoxycholate salts and the like or heterogeneous polyoxyethylene detergents such as TweenTM, BRIGTM or TrltonTM.
Utilization of this method allows reconstitution of antigens, more specifically proteins, into the liposomes with retention of biological activities, and eventually efficient association with the cochleates. This avoids organic solvents, sonication, or extreme pH, temperature, or pressure all of which may have an adverse effect upon efficient reconstitution of the antigen in a biologically active form.
Hydrogel-isolated cochleates may contain a combination of various biologically relevant molecules as appropriate.
The formation of small-sized cochleates (with or without a biologically relevant molecule) is achieved by adding a positively charged molecule to the aqueous two-phase polymer solution containing liposomes. In the above procedure for makmg cochleates, the positively charged molecule can be a polyvalent cation and more specifically, any divalent cation that can induce the formation of a cochleate. In a preferred embodlment, the divalent cations include Ca++, Zn++, Ba' and Mg' or other elements capable of forming divalent ions or other structures having multiple positive charges capable of chelating and bridging negatively charged lipids. Addition of positively charged molecules to liposome-containing solutions is also used to precipitate cochleates from the aqueous solution.
WO 00/42989 PCT/[JS00/01684 To isolate the cochleate structures and to remove the polyrner solution, cochleate precipitales are repeatedly washed ~4'!th a buffer containing a positively charged niolecule, and more preferably, a divalent cation. Addition of a positively charged molecule to the wash buffer ensures that the cochleate structures arc maintained throughout the wash step;
and that they remain as precipitates.
The medium in which the cochleates are suspended can contain salt such as calcium chloride, zinc chloride, cobalt chloride, sodium chloride, sodium sulfate, potassium sulfate, ammonium sulfate, magnesium sulfate and sodium carbonate. The medium can contain polymers such as Tween 80 or BRIG or Triton. T'he biologically relevant nlolccule-cochleate is made by diluting into an appropriate biologically acceptable carrier (e.g., a divalent cation-containing buffer).
The cochleate particles can be enteric. The cochleate particles can be placed within gelatin capsules and the capsule can be enteric coated.
In the preparations of the present invention certain hydrophobic materials can be added to provide enhanced absorption properties for oral delivery of biologically relevant molecules. These materials are preferably selected from the group consisting of long chain carboxylic acids, long chain carboxylic acid esters, long chain carboxylic acid alcohols and mixtures t.hereof. The hydrophobic rnaterials cati be added either initially to the lipid prior to the formation of liposomes or in a later step in the fomi of a fat vehicle such as an emulsion.
The skilled artisan can determine the most efficacious and therapeutic means for effecting treatment practicing the instant invention. Reference can also be made to any of numerous authorities and references including, for exaniple, "Goodman &
Gillman's, The Pharmaceutical Basis for Therapeutics", ((0 i Ed., Goodman et al., eds., MacMillan Publ. Co., New York, 1980).
The invention will now be described by exaniples which are not to be considered as limiting the invention. In the examples, unless otherwise indicated, all ratios, percents and amounts are by weight.
EXAMPLES
Example 1. Preparation of empty hydrogel-isolated cochleates from dioleoylphosphatidylserine precipitated with calcium Step I: Preparation of small unilaniellar vesicles from dioleoylphosphatidylserine.
A solution of dioleoyl phosphatidylserine (DOPS, Avanti Polar Lipids, Alabaster, AL, USA) in chlorofomi (10 mg/ml) was placed in a round-bottom flask and dried to a film using a Buchi rotavapor at 35 C. "I'he rotavapor was sterilized by flashing nitrogen gas through a 0.2 m filter. The following steps were carried out in a sterile hood. The dried lipid film was hydrated with de-ionized water at the concentration of 10 mg lipid/ml. The hydrated suspension was purged and sealed with nitrogen, then sonicated in a cooled bath sonicator (Laboratory Supplies Com., Inc.). Sonication was continued (for several seconds to several miiiutes depending on lipid quantity and nature) until the suspension became clear (suspension A) and there were no liposomes apparently visible under a phase contrast microscope with a 1000X magnification. Laser light scattering (weight analysis, Coulter N4 Plus) indicates that the mean diameter is 35.7 + 49.7 nm.
Step 2: Prepai-ation of hydrogel isolated cochleates The liposome suspension obtained in step 1 was then mixed witti 40 % w/w dextran-500,000 (Sigma) in a suspension of 2/1 v/v Dextran/liposome. This mixture was then injected with a syringe into 15 % w/w PEG-8,000 (Sigma) [PEG 8000/(suspension A)] under magnetic stirring to result in suspension B. The i-ate of the stirring was 800-1,000 rptn. A
CaC12 solution (100 mM) was added to the suspension to reach the final concentration of I
mM.
Stirring was continued for one hour, then a washing buffer containing I mM
CaClz and 150 mM NaCI was added to suspension B at the volumetric ratio of 1:1.
'I'he suspension was vortexed and centrifuged at 3000 rpm, 2-4 C, for 30 min. After the supernatant was removed, additional washing buffer was added at the volumetric ratio of' 0.5:1, followed by centrifugation under the same conditions. A schematic of this new process of obtaining cochleates is detailed in Figure 1. The resultant pcllet was reconstitutcd with the same buffer to the dcsired concentration. Laser light scattering (weight analysis, Coultcr N4 Plus) indicates that the mean diameter for the cochleate is 407.2 + 85 nm (figure 2b).
Example 2. Preparation of empty hydrogel-isolated cochleates from a mixture of dioleoylphosphatidylserine and 1,2-Distearoyl-sn-glycerol-3-phosphoethanolamine-n-(poly(ethylene glycol)-5000, DSPE-PEG) precipitated with calcium Step 1: Preparatlon ofsruall unilamellar vesicles.
A solution of dioleoylphosphatidylserine (DOPS) and 1,2-distearoyl-sn-glycerol-phosphoethanolamine-n-(poly(ethylene glycol)-5000), (DSPE-PEG, Avanti Polar Lipids, Alabaster, AL, USA) in chloroform (ratio of DOPS:DSPS-PEG = 100:1, w:w) was placed in a round-bottom flask and dried to a film using a Buchi rotavapor at 35 C. The rotavapor was sterilized by flashing nitrogen gas through a 0.2 m filter. The following steps were carried out in a sterile hood. The dried lipid film was hydrated with de-ionized water to a concentration of 10 mg lipid/ml. The hydrated suspension was purged and sealed with nitrogen, then sonicated in a cooled bath sonicator (Laboratory Supplies Com., Inc.).
WO 00/42989 PC"T/US00101684 Sonication was continued (for several seconds to several minutes depending on lipid quantity and nattire) until the suspension became clear (suspension A) and there were iio liposonies apparently visible under a phase coiltrast optical microscope witll a 1000X
magnification.
Step 2: Preparation of hydrogel isolated cochleates 5 The liposome suspension obtained in step I was then rnixed with 40 % w/w dextran-500,000 in a suspension of 2/1 v/v Dextran/liposome. This niixture was then injected via a syringe into 15 % w/w PEG-8,000 [PEG 8000/(suspension A)] under magnetic stirring to result in suspension B. The rate of the stirring was 800-1,000 rprn. A CaCI2 solution (100 mM) was added to the suspension to reach the final concentration of 1 mM.
Stirring was continued for one hour, then a washing buffer containing 1 mM
CaClz and 150 mM NaCI was added to suspension B at the volumetric ratio of 1:1. The suspension was vortexed and centrifuged at 3000 rpm, 2-4 C, for 30 min. After the supernatant was removed, additional washing buffer was added at the volumetric ratio of 0.5:1.
followed by centrifugation under the same conditions. A schematic of this new process of obtaining cochleates is detailed in Figure 1. The resulting pellet was reconstituted with the same buffer to the desired concentration. Phase contrast optical microscopy indicates the forrnation of uniform, very small, needie-like cochleates.
Example 3. Preparation of empty hydrogel-isolated cochleates from a mixture of dioleoylphosphatid,ylserine and n-octyl-beta-D-gluco-pyranoside precipitated with calcium Step I: Preparation of srnall unilmnellar vesicles.
A solution of dioleoylphosphatidylserine (DOPS) in chloroform was placed in a round-bottom flask and dried to a film using a Buchi rotavapor at 35 C. The rotavapor was sterilized by flashing nitrogen gas through a 0.2 m filter. "I'he following steps were carried out in a sterile hood. The dried lipid filni was hydrated with a solution of n-octyl-beta-D-gluco-pyranoside (OCG) at I mg/ml at a ratio of DOPS : OCG of 10:1 w:w. "1'he hydi-ated suspension was purged and sealed with nitrogen, then sonicated briefly in a cooled bath sonicator.
Step 2: Preparation nf hvdragel isvlaied cocltleates The suspension obtained in step I was theri rnixed with 40 `% w/w dextran-500,000 in a suspension of 2/1 v/v Dextran/liposome. "I'his niixture was then injected via a syringe into % w/w PEG-8,000 [PEG 8000/(suspension A)] under niagnetic stirring to result in suspension R. The rate of the stirring was 800-1,000 rpm. A CaC12 solution (100 mM) was 10 added to the suspension to reach the final concentration of 1 mM.
Stirring was continued for one hour, then a washing buffer containing 1 mM
CaC1Z
and 150 mM NaCI was added to suspension B at the volunietric ratio of 1:1. The suspension was vortexed and centrifugcd at 3000 rpni, 2-4 C, for 30 min. After the supernatant was removed, additional wasliing buffer was added at the volumetric ratio of 0.5:1, followed by 15 centrifugation under the same conditions. A schematic of this new process of obtaining cochleates is detailed in Figure 1. The resulting pellet was reconstituted with the same buffer to the desired concentration. Phase contrast optical microscopy indicates the formation of unifonn, very small, needle-Iike cochleates.
Example 4. Preparation of Amphotericin B-loaded hydrogel-isolated cochleates precipitated with calcium Step 1: Preparation of sniall unilamellar Aml3-loaded, vesicles from dioleoylphosphatidylserine.
A mixture of dioleoyl phosphatidylserine (DOPS) in chlorofonn (10 mg/rnl) and AmB in methanol (0.5mg/ml) at a niolar ratio of 10: l was placed in a round-bottom flask and dried to a film using a Buchi rotavapor at 40 C. 'The rotavapor was sterilized by flashing nitrogen gas through a 0.2 m filter. Ttie following steps were carried out in a sterile hood.
The dricd lipid film was hydrated with de-ionized water at the concentration of 10 mg lipid/rnl. The hydrated suspension was purged anci sealed with nitrogen, then sonicated in a cooled bath sonicator. Sonication was continued (for several seconds to several minutes depcnding on lipid quantity and nature) until the suspension became clear yellow (suspension A) and there were no liposomes apparently visible under a phase contrast microscope with a 1000X magnification.
Step 2: Preparation of AmB-loaded, hydrogel- isolated cochleates The liposome suspension obtaincd in step 1 was then mixed with 40 % w/w dextran-500,000 in a suspension of 2/1 v/v Dextran/liposome. This niixture was then injected via a syringe into 15 % w/w PEG-8,000 [PEG 8000/(suspcnsion A)] under niagnetic stirring to result in suspension B. The rate of the stirring was 800-1,000 rpm. A CaCl2 solution (100 mM) was added to the suspension to reach the final concentration of 1mM.
Stirring was continued for one hour, then a washing buffer containing 1 mM
CaClz and 150 mM NaCl was added to suspension B at the volumetric ratio of 1: 1. The suspension was vortexed and centrifuged at 3000 rpm, 2-4 C, for .30 min. After the supernatant was removed, additional washing buffer was added at the volumetric ratio of 0.5:1, followed by centrifugation under the same conditions. A schematic of this new process of obtaining cochleates is detailed in Figure 1. The resulting pellet was reconstituted with the same buffer to the desired concentration. Laser light scattering (weight analysis, Coulter N4 Plus) indicate that the AmB-cochleates mean diameter was 407.3 + 233.8 nm (figure 2a).
Example 5. Preparation of Doxorubicin (DXR) loaded hydrogel isolated cochteates precipitated with calcium Step :1 Preparatioit of small zuulamell(u-1),kR-loarled vesicles jrom dioleoylphosphatidylserine.
A mixture of dioleoylphosphatidylserine (DOPS) in chlorofonn (10 mg/n-il) and (DXR) in methanol (0.5mg/ml) at a molar ratio of 10:1 was placed in a round-bottom flask and dried to a film using a Buchi rotavapor at room temperature. The rotavapor was sterilized by flashing nitrogen gas through a 0.2 lun filter. The following steps were carried out in a sterile hood. The dried lipid film was hydrated with de-ionized water at the concentration of 25 mg lipid/ml. The hydrated suspension was purged and sealed with nitrogen, then sonicated in a cooled bath sonicator. Sonication was continued (for several seconds to several minutes depending on lipid quantity and nature) uritil the suspension became clear pink (suspension A) and there were no liposomes apparently visible under phase contrast microscope with a 1000X maguification.
Step 2: Preparation of DXR-loatled, hydrogel isolated cochleates 5 ml of the liposome suspension obtained in step I was then mixed with 40 %
w/w dextran-500,000 (Sigma) in a suspension of 2/1 v/v Dextrari/liposome. This mixture was then injected via a syringe into 15 % w/w PEG-8,000 [PEG 8000/(suspension A)]
under magnetic stirring to result in suspension B. The rate of the stirring was 800-1,000 rpm. A
CaClz solution (100 mM) was added to the suspension to reach the final concentration of 1mM.
Stirring was continued for one hour, then a washing buffer containing 1 mM
CaC12 and 150 mM NaCI was added to suspension B at the volumetric ratio of 1:1. The suspension was vortexed and centrifuged at 6400 rpm, 2-4 C, for 30 min. A schematic of this new process of obtaining cochleates is detailed in Figure i."The resulting pellet was reconstituted with the same buffer to the desired concentration. Laser light scattering (weight analysis, Coulter N4 Plus) confirmed the fonnation of small DXR-cochlcates.
Example 6. Preparation of Cyclosporin A (CSPA) -loaded hydrogel isolated cochleates ' precipitated with calcium Step I: Preparation of srnall unilaniellar CSPA-loaded vesicle.r from dioleoylphosphatid vlserine.
A mixture of dioleoylphosphatidylserine (DOPS) in chlorofonn (10 mg/ml) and CSPA in methanol (0.5mg/ml) at a molar ratio of 10:1 was placed in a round-bottom flask and dried to a fi]m using a Buchi rotavapor at room temperature. The rotavapor was sterilized by flashing nitrogen gas through a 0.2 m filter. The following steps were carried out in a sterile hood. The dried lipid film was hydrated with dc-ionized water at the concentration of 10 mg lipid/ml. The hydrated suspension was purged and sealed with nitrogen, then sonicated in a cooled bath sonicator. Sonication was continued (for several seconds to several minutes depending on lipid quantity and nature) until the suspension became clear (suspension A) and there were no liposomes apparently visible under a phase contrast microscope with a 1000X magnification.
Step 2 : Preparation of CSPA-loaded, hydrogel isolated, cochleates The liposome suspension obtained in step 1 was then mixed with 40 % w/w dextran-500,000 in a suspension of 2/1 v/v Dextran/liposome. This mixture was then injected via a syringe into 15 % w/w PEG-8,000 (Sigma) [PEG 8000/(suspension A)] under magnetic stirring to result in suspension B. The rate of the stirring was 800-1,000 rpnl. A CaCI2 solution (100 mM) was added to the suspension to reach the final concentration of ImM.
Stirring was continued for one hour, then a washing buffer containing 1 mM
CaC12 and 150 mM NaCI was addcd to suspension B at the volumetric ratio of 1: 1. The suspension was vortexed and centrifuged at 3000 rpm, 2-4 C, for 30 min. After the supernatant was removed, additional washing bufJer was added at the volunietric ratio of 0.5:1, followed by centrifugation under the same conditions. A scliematic of this new process of obtaining cochleates is detailed in Figure 1. The resultitig pellet was reconstituted with the same buffer to the desired concentration. Laser Iigllt scattering (weight analysis, Coulter N4 Plus) confirmed the formatiort of sniall CSPA-coclileates.
Example 7. Preparation of Nelfinavir (NV1R)loaded hydrogel isolated cochleates precipitated with calciuni Step 1: Preparation of small unilamellar NVIR-loaded vesicles from diole.oylphosPhatidyl,serine.
A mixture of diolcoylphosphatidylserine (DOPS) in chloroform (10 mg/ml) and NViR in methanol (0.5mg/ml) at a molar ratio of 10:1 was placed in a round-bottom flask and dried to a film using a Buchi rotavapor at RT. The rotavapor was sterilized by flashing nitrogen gas through a 0.2 m filter. The following steps were carried out in a sterile hood, The dried lipid film was hydrated with de-ionized water at the concentration of 10 mg lipid/ml. The hydrated suspension was purged and sealed with nitrogen, then sonicated in a cooled bath sonicalor. Sonication was continued (for several seconds to several minutes depending on lipid quantity and nature) until the suspension becanle clear (suspension A) and there were no liposonies apparentlv visible under a phase contrast microscope with a 1000X
magnification.
Step l: Preparation of NVIR-loadetl, Jrydrogel isolated, cochleates The liposome suspension obtained in stcp I was then niixed with 40 % w/w dextran-500,000 in a suspension of 2/1 v/v Dcxtran/liposome. This mixture was then injected via a syringe into 15 % w/w PEG-8,000 [PEG 8000/(suspension A)] undcr niagnetic stirring to result in suspension B. The rate of the stirring was 800-1,000 rpm. A CaC12 solution (100 mM) was added to the suspension to reach the final concentration of 1mM.
Stirring was continued for one hour, then a washing buffer containing 1 mM
CaCI2 and 150 mM NaCI was added to suspension B at the volumetric ratio of 1:1. The suspension was vortexed and centrifuged at 3000 rpm, 2-4 C, for 30 min. After the supernatant was removed, additional washing buffer was added at the volumetric ratio of 0.5:1, followed by centrifugation under the same conditions. A scheniatic of this new process of obtaining cochleates is detailed in Figure 1. 'I'he resulting pellet was reconstituted with the same buffer to the desired concentration. Laser light scattering (weight analysis, Coulter N4 Plus) confirmed the formatioii of small NV1R-cochleates.
Example 8. Preparation of Rifampin (RIF) -loaded hydrogel-isolated cocbleates precipitated with calciu[n Step 1: Preparation of small urtilaniellar RIF-loaded vesicles from dioleovlphosphatidyl serine.
A mixture of dioleoylphosphatidylscrine (DOPS) in chloroform (10 mg/ml) and RIF
in methanol (0.5mg/mi) at a molar ratio of 10:1 was plaeed in a round-bottom flask and dried to a film using a Buchi rotavapor at RT. The rotavapor was sterilized by flashing nitrogen gas through a 0.2 m filter. The following steps were carried out in a sterile hood. '1'he dried lipid film was hydrated with de-ionized water at the concentration of 10 mg lipid/ml. The hydrated suspension was purged and sealed with nitrogen, then sonicated in a cooled bath sonicator. Sonication was continued (for several seconds to several minutes depending on lipid quantity and nature) until the suspension became clear (suspension /1'i and there were no liposomes apparently visible under a phase contrast microscope with a 1000X
magnification.
Step 2: Preparation of RIF-loaded, hydrogel isolate, d cochleates The liposome suspension obtained in step I was then ntixed with 40 % w/w dextran-500,000 (Sigma) in a suspcnsion of 2/1 v/v Dcxtran/liposome. This mixture was then injected via a syringe into 15 % w/w PEG-8,000 (Sigma) [PFG 8000/(suspension A)] under magnetic stirring to result in suspension B. The rate of the stirring was 800-1,000 rpm. A
CaClz solution (100 mM) was added to the suspension to reach the final concentration of 1mM.
Stirring was continued for one hour, then a washing buffer containing 1 mM
CaC12 and 150 mM NaCl was added to suspension B at the volumetric ratio of 1:1. The suspension was vortexed and centrifuged at 3000 rpm, 2-4 C, for 30 min. After the supematant was removed, additional washing bufler was added at the volumetric ratio of 0.5:1, followed by centrifugation under the same conditions. A schematic of this new process of obtaining cochleates is detailed in Figure 1. The resulting pellet was reconstituted with the sacne buffer to the desired concentratioti. Laser light scattering (weight analysis, Coulter N4 Plus) eonfirmed the formation of small RIF-cochleates.
c) adding the detergent-lipid/polymer A suspension into a solution comprising pol_ymer B, wherein polymer A and polymer B are imrniscible, thereby creatin(; a two-phase polymer system;
d) adding a solution of a cationic moiety to the two-phase polymer system; and e) washing the two-phase polymer systeni to remove the polymer.
A lyopliilization procedure can be applied and the lyophilized biologically relevant molecule-cochleate complex can be filled into soft or hard gelatin capsules, tablets or othcr dosage form, for systemic, dermal or mucosal dclivery.
This process leads to a small-sized particle with a narrow sizc range that allows efficient oral delivery of biologically relevant molecules. 'The biologically relevant molecule partitions into either or both lipid bilayers and interspace, and the biologically relevant molecule is released from the cochlcate particles by dissociation of the particles in vivo.
Alternative routes of administration may bc systemic such as intramuscular, subcutancous or intravenous or mucosal such as intranasal, intraocular, intravaginal, intraanal, parenteral or intrapulmonary. Appropriate dosages arc detenninable by, for example, dose-response experiments in laboratory animals or in clinical trials and taking into account body weight of the patient, absorption rate, half-life, disease severity and the like. The number of doses, daily dosage and course of treatment may vary from individual to individual.
Other delivery routes can be dermal, transdermal or intradennal.
The first step of the new process of the present invention, which is the preparation of small liposomes, can be achieved by standard methods stich as sonication or microfluidization or other related methods (see for example Liposome Tcchnology, Liposome Preparation and Related Techniques, Edited by Gregory Gregoriadis, Vol I, 2nd Edition, CRC Press, 1993).
The addition, preferably by injection, of polymer A/liposome suspension into polymer B can be achieved mechanically by using a syringe pump at an appropriate controlled rate, for example a rate of 0.1 ml/min to 50 ml/min and preferably at a rate of 1 to 10 ml/min.
The lipids of the present invention are non-toxic lipids and include, but are not limited to simple lipids which are found in animal and plant cell membranes.
Preferably the lipid is a negatively charged lipid, more preferably a negatively charged phospholipid, and even more preferably a lipid from the group of phosphatidylserine, phosphatidylinositol, phosphatidic acid, and phosphatidyl glycerol. The lipids may also include minor amounts of zwitterionic lipids, cationic lipids or neutral lipids capable of forming hydrogen bonds to a biologically relevant molecule such as PEGylated lipid.
The polymers A and B of the present invention can be of any biocompatible polymer classes that can produce an aqueous two-phase system. For example, polymer A
can be, but is not limited to, dextran 200,000-500,000, Polyethylene glycol (PEG) 3,400-8,000; polymer B can be, but is not limited to, polyvinylpyrrolidone (PVP), polyvinylalcohol (PVA), FicollT"' 30,000-50,000, polyvinyl methyl ether (PVMB) 60,000-160,000, PEG 3,400-8,000.
The concentration of polymer A can range from between 2-20% w/w as the final concentration depending on the nature of the polymer. The same concentration range can be applied for polymer B. Examples of suitable two-phase systems are Dextran/PEG, 5-20% w/w Dextran 200,000-500,000 in 4-10% w/w PEG 3,400-8,000; Dextran/PVP 10-20% w/w Dextran 200,000-500,000 in 10-20% w/w PVP 10,000-20,000; Dextran/PVA 3-15% w/w Dextran 200,000-500,000 in 3-15% w/w PVA 10,000-60,000; Dextran/FicollT'" 10-20% w/w Dextran 9 PCT/1iS00/01684 200,000-500,000 in 10-20% w/w Ficoll 30,000-50,000; PF,G/PVME 2-10% w/w PEG
3,500-35,000 in 6-15% w/w PVME 60,000-1 60,000.
The biologically rclcvant molecule may be an organic molecule that is hydrophobic in aqueous media. The biologically rclevant molecule may he a drug, and the drug may be an antiviral, an anesthetic, an anti-infeetious, an antifungal, an anticancer, an immunosuppressant, a steroidal anti-inflammatory, a non-steroidal anti-inflammatory, a tranquilizer or a vasodilatory agent. Examples includc Amphotericin B, acyclovir, adriamycin, cabamazepine, melphalan, nifedipine, indomethacin, naproxen, estrogens, testosterones, steroids, phenytoin, ergotamines, cannabinoids raparnycin.
propanidid, propofol, alphadione, echinomycine, miconazole nilrate, teniposide, taxol, and taxotere.
The biologically relevant molecule may be a polypeptide such as cyclosporin, angiotensin 1, 11 and III, enkephalins and their analogs, ACTH, anti-inflarnmatory peptides 1, II, III, bradykinin, calcitonin, b-endorphin, dinorphin, leucokinin, leutinizing hormone releasing hormone (LHRH), insulin, neurokinins, sornatostatin, substance P, thyroid releasing hon none (TRH) and vasopressin.
The biologically relevant molecule may be an antigen, but the antigen is not limited to a protein antigen. The antigen can also be a carbohydrate or a polynucleotide such as DNA.
Examples of antigenic proteins include envelope glycoproteins from influenza or Sendai viruses, animal cell membrane proteins, plant cell membrane proteins, bacterial membrane proteins and parasitic membrane protein.
The biologically rclevant molecule is extracted from the source particle, cell, tissue, or organism by known methods. Biological activity of biologically relevant molecules need not be maintained. However, in some instances (e.g., where a protein has membrane fusion or ligand binding activity or a complex conformation which is recognized by the immune system), it is desirable to maintain the biological activity. In these instances, an extraction buffer containing a detergent which does not destroy the biological activity of the membrane protein is used. Suitable detergents include ionic detergents such as cholate salts, deoxycholate salts and the like or heterogeneous polyoxyethylene detergents such as TweenTM, BRIGTM or TrltonTM.
Utilization of this method allows reconstitution of antigens, more specifically proteins, into the liposomes with retention of biological activities, and eventually efficient association with the cochleates. This avoids organic solvents, sonication, or extreme pH, temperature, or pressure all of which may have an adverse effect upon efficient reconstitution of the antigen in a biologically active form.
Hydrogel-isolated cochleates may contain a combination of various biologically relevant molecules as appropriate.
The formation of small-sized cochleates (with or without a biologically relevant molecule) is achieved by adding a positively charged molecule to the aqueous two-phase polymer solution containing liposomes. In the above procedure for makmg cochleates, the positively charged molecule can be a polyvalent cation and more specifically, any divalent cation that can induce the formation of a cochleate. In a preferred embodlment, the divalent cations include Ca++, Zn++, Ba' and Mg' or other elements capable of forming divalent ions or other structures having multiple positive charges capable of chelating and bridging negatively charged lipids. Addition of positively charged molecules to liposome-containing solutions is also used to precipitate cochleates from the aqueous solution.
WO 00/42989 PCT/[JS00/01684 To isolate the cochleate structures and to remove the polyrner solution, cochleate precipitales are repeatedly washed ~4'!th a buffer containing a positively charged niolecule, and more preferably, a divalent cation. Addition of a positively charged molecule to the wash buffer ensures that the cochleate structures arc maintained throughout the wash step;
and that they remain as precipitates.
The medium in which the cochleates are suspended can contain salt such as calcium chloride, zinc chloride, cobalt chloride, sodium chloride, sodium sulfate, potassium sulfate, ammonium sulfate, magnesium sulfate and sodium carbonate. The medium can contain polymers such as Tween 80 or BRIG or Triton. T'he biologically relevant nlolccule-cochleate is made by diluting into an appropriate biologically acceptable carrier (e.g., a divalent cation-containing buffer).
The cochleate particles can be enteric. The cochleate particles can be placed within gelatin capsules and the capsule can be enteric coated.
In the preparations of the present invention certain hydrophobic materials can be added to provide enhanced absorption properties for oral delivery of biologically relevant molecules. These materials are preferably selected from the group consisting of long chain carboxylic acids, long chain carboxylic acid esters, long chain carboxylic acid alcohols and mixtures t.hereof. The hydrophobic rnaterials cati be added either initially to the lipid prior to the formation of liposomes or in a later step in the fomi of a fat vehicle such as an emulsion.
The skilled artisan can determine the most efficacious and therapeutic means for effecting treatment practicing the instant invention. Reference can also be made to any of numerous authorities and references including, for exaniple, "Goodman &
Gillman's, The Pharmaceutical Basis for Therapeutics", ((0 i Ed., Goodman et al., eds., MacMillan Publ. Co., New York, 1980).
The invention will now be described by exaniples which are not to be considered as limiting the invention. In the examples, unless otherwise indicated, all ratios, percents and amounts are by weight.
EXAMPLES
Example 1. Preparation of empty hydrogel-isolated cochleates from dioleoylphosphatidylserine precipitated with calcium Step I: Preparation of small unilaniellar vesicles from dioleoylphosphatidylserine.
A solution of dioleoyl phosphatidylserine (DOPS, Avanti Polar Lipids, Alabaster, AL, USA) in chlorofomi (10 mg/ml) was placed in a round-bottom flask and dried to a film using a Buchi rotavapor at 35 C. "I'he rotavapor was sterilized by flashing nitrogen gas through a 0.2 m filter. The following steps were carried out in a sterile hood. The dried lipid film was hydrated with de-ionized water at the concentration of 10 mg lipid/ml. The hydrated suspension was purged and sealed with nitrogen, then sonicated in a cooled bath sonicator (Laboratory Supplies Com., Inc.). Sonication was continued (for several seconds to several miiiutes depending on lipid quantity and nature) until the suspension became clear (suspension A) and there were no liposomes apparently visible under a phase contrast microscope with a 1000X magnification. Laser light scattering (weight analysis, Coulter N4 Plus) indicates that the mean diameter is 35.7 + 49.7 nm.
Step 2: Prepai-ation of hydrogel isolated cochleates The liposome suspension obtained in step 1 was then mixed witti 40 % w/w dextran-500,000 (Sigma) in a suspension of 2/1 v/v Dextran/liposome. This mixture was then injected with a syringe into 15 % w/w PEG-8,000 (Sigma) [PEG 8000/(suspension A)] under magnetic stirring to result in suspension B. The i-ate of the stirring was 800-1,000 rptn. A
CaC12 solution (100 mM) was added to the suspension to reach the final concentration of I
mM.
Stirring was continued for one hour, then a washing buffer containing I mM
CaClz and 150 mM NaCI was added to suspension B at the volumetric ratio of 1:1.
'I'he suspension was vortexed and centrifuged at 3000 rpm, 2-4 C, for 30 min. After the supernatant was removed, additional washing buffer was added at the volumetric ratio of' 0.5:1, followed by centrifugation under the same conditions. A schematic of this new process of obtaining cochleates is detailed in Figure 1. The resultant pcllet was reconstitutcd with the same buffer to the dcsired concentration. Laser light scattering (weight analysis, Coultcr N4 Plus) indicates that the mean diameter for the cochleate is 407.2 + 85 nm (figure 2b).
Example 2. Preparation of empty hydrogel-isolated cochleates from a mixture of dioleoylphosphatidylserine and 1,2-Distearoyl-sn-glycerol-3-phosphoethanolamine-n-(poly(ethylene glycol)-5000, DSPE-PEG) precipitated with calcium Step 1: Preparatlon ofsruall unilamellar vesicles.
A solution of dioleoylphosphatidylserine (DOPS) and 1,2-distearoyl-sn-glycerol-phosphoethanolamine-n-(poly(ethylene glycol)-5000), (DSPE-PEG, Avanti Polar Lipids, Alabaster, AL, USA) in chloroform (ratio of DOPS:DSPS-PEG = 100:1, w:w) was placed in a round-bottom flask and dried to a film using a Buchi rotavapor at 35 C. The rotavapor was sterilized by flashing nitrogen gas through a 0.2 m filter. The following steps were carried out in a sterile hood. The dried lipid film was hydrated with de-ionized water to a concentration of 10 mg lipid/ml. The hydrated suspension was purged and sealed with nitrogen, then sonicated in a cooled bath sonicator (Laboratory Supplies Com., Inc.).
WO 00/42989 PC"T/US00101684 Sonication was continued (for several seconds to several minutes depending on lipid quantity and nattire) until the suspension became clear (suspension A) and there were iio liposonies apparently visible under a phase coiltrast optical microscope witll a 1000X
magnification.
Step 2: Preparation of hydrogel isolated cochleates 5 The liposome suspension obtained in step I was then rnixed with 40 % w/w dextran-500,000 in a suspension of 2/1 v/v Dextran/liposome. This niixture was then injected via a syringe into 15 % w/w PEG-8,000 [PEG 8000/(suspension A)] under magnetic stirring to result in suspension B. The rate of the stirring was 800-1,000 rprn. A CaCI2 solution (100 mM) was added to the suspension to reach the final concentration of 1 mM.
Stirring was continued for one hour, then a washing buffer containing 1 mM
CaClz and 150 mM NaCI was added to suspension B at the volumetric ratio of 1:1. The suspension was vortexed and centrifuged at 3000 rpm, 2-4 C, for 30 min. After the supernatant was removed, additional washing buffer was added at the volumetric ratio of 0.5:1.
followed by centrifugation under the same conditions. A schematic of this new process of obtaining cochleates is detailed in Figure 1. The resulting pellet was reconstituted with the same buffer to the desired concentration. Phase contrast optical microscopy indicates the forrnation of uniform, very small, needie-like cochleates.
Example 3. Preparation of empty hydrogel-isolated cochleates from a mixture of dioleoylphosphatid,ylserine and n-octyl-beta-D-gluco-pyranoside precipitated with calcium Step I: Preparation of srnall unilmnellar vesicles.
A solution of dioleoylphosphatidylserine (DOPS) in chloroform was placed in a round-bottom flask and dried to a film using a Buchi rotavapor at 35 C. The rotavapor was sterilized by flashing nitrogen gas through a 0.2 m filter. "I'he following steps were carried out in a sterile hood. The dried lipid filni was hydrated with a solution of n-octyl-beta-D-gluco-pyranoside (OCG) at I mg/ml at a ratio of DOPS : OCG of 10:1 w:w. "1'he hydi-ated suspension was purged and sealed with nitrogen, then sonicated briefly in a cooled bath sonicator.
Step 2: Preparation nf hvdragel isvlaied cocltleates The suspension obtained in step I was theri rnixed with 40 `% w/w dextran-500,000 in a suspension of 2/1 v/v Dextran/liposome. "I'his niixture was then injected via a syringe into % w/w PEG-8,000 [PEG 8000/(suspension A)] under niagnetic stirring to result in suspension R. The rate of the stirring was 800-1,000 rpm. A CaC12 solution (100 mM) was 10 added to the suspension to reach the final concentration of 1 mM.
Stirring was continued for one hour, then a washing buffer containing 1 mM
CaC1Z
and 150 mM NaCI was added to suspension B at the volunietric ratio of 1:1. The suspension was vortexed and centrifugcd at 3000 rpni, 2-4 C, for 30 min. After the supernatant was removed, additional wasliing buffer was added at the volumetric ratio of 0.5:1, followed by 15 centrifugation under the same conditions. A schematic of this new process of obtaining cochleates is detailed in Figure 1. The resulting pellet was reconstituted with the same buffer to the desired concentration. Phase contrast optical microscopy indicates the formation of unifonn, very small, needle-Iike cochleates.
Example 4. Preparation of Amphotericin B-loaded hydrogel-isolated cochleates precipitated with calcium Step 1: Preparation of sniall unilamellar Aml3-loaded, vesicles from dioleoylphosphatidylserine.
A mixture of dioleoyl phosphatidylserine (DOPS) in chlorofonn (10 mg/rnl) and AmB in methanol (0.5mg/ml) at a niolar ratio of 10: l was placed in a round-bottom flask and dried to a film using a Buchi rotavapor at 40 C. 'The rotavapor was sterilized by flashing nitrogen gas through a 0.2 m filter. Ttie following steps were carried out in a sterile hood.
The dricd lipid film was hydrated with de-ionized water at the concentration of 10 mg lipid/rnl. The hydrated suspension was purged anci sealed with nitrogen, then sonicated in a cooled bath sonicator. Sonication was continued (for several seconds to several minutes depcnding on lipid quantity and nature) until the suspension became clear yellow (suspension A) and there were no liposomes apparently visible under a phase contrast microscope with a 1000X magnification.
Step 2: Preparation of AmB-loaded, hydrogel- isolated cochleates The liposome suspension obtaincd in step 1 was then mixed with 40 % w/w dextran-500,000 in a suspension of 2/1 v/v Dextran/liposome. This niixture was then injected via a syringe into 15 % w/w PEG-8,000 [PEG 8000/(suspcnsion A)] under niagnetic stirring to result in suspension B. The rate of the stirring was 800-1,000 rpm. A CaCl2 solution (100 mM) was added to the suspension to reach the final concentration of 1mM.
Stirring was continued for one hour, then a washing buffer containing 1 mM
CaClz and 150 mM NaCl was added to suspension B at the volumetric ratio of 1: 1. The suspension was vortexed and centrifuged at 3000 rpm, 2-4 C, for .30 min. After the supernatant was removed, additional washing buffer was added at the volumetric ratio of 0.5:1, followed by centrifugation under the same conditions. A schematic of this new process of obtaining cochleates is detailed in Figure 1. The resulting pellet was reconstituted with the same buffer to the desired concentration. Laser light scattering (weight analysis, Coulter N4 Plus) indicate that the AmB-cochleates mean diameter was 407.3 + 233.8 nm (figure 2a).
Example 5. Preparation of Doxorubicin (DXR) loaded hydrogel isolated cochteates precipitated with calcium Step :1 Preparatioit of small zuulamell(u-1),kR-loarled vesicles jrom dioleoylphosphatidylserine.
A mixture of dioleoylphosphatidylserine (DOPS) in chlorofonn (10 mg/n-il) and (DXR) in methanol (0.5mg/ml) at a molar ratio of 10:1 was placed in a round-bottom flask and dried to a film using a Buchi rotavapor at room temperature. The rotavapor was sterilized by flashing nitrogen gas through a 0.2 lun filter. The following steps were carried out in a sterile hood. The dried lipid film was hydrated with de-ionized water at the concentration of 25 mg lipid/ml. The hydrated suspension was purged and sealed with nitrogen, then sonicated in a cooled bath sonicator. Sonication was continued (for several seconds to several minutes depending on lipid quantity and nature) uritil the suspension became clear pink (suspension A) and there were no liposomes apparently visible under phase contrast microscope with a 1000X maguification.
Step 2: Preparation of DXR-loatled, hydrogel isolated cochleates 5 ml of the liposome suspension obtained in step I was then mixed with 40 %
w/w dextran-500,000 (Sigma) in a suspension of 2/1 v/v Dextrari/liposome. This mixture was then injected via a syringe into 15 % w/w PEG-8,000 [PEG 8000/(suspension A)]
under magnetic stirring to result in suspension B. The rate of the stirring was 800-1,000 rpm. A
CaClz solution (100 mM) was added to the suspension to reach the final concentration of 1mM.
Stirring was continued for one hour, then a washing buffer containing 1 mM
CaC12 and 150 mM NaCI was added to suspension B at the volumetric ratio of 1:1. The suspension was vortexed and centrifuged at 6400 rpm, 2-4 C, for 30 min. A schematic of this new process of obtaining cochleates is detailed in Figure i."The resulting pellet was reconstituted with the same buffer to the desired concentration. Laser light scattering (weight analysis, Coulter N4 Plus) confirmed the fonnation of small DXR-cochlcates.
Example 6. Preparation of Cyclosporin A (CSPA) -loaded hydrogel isolated cochleates ' precipitated with calcium Step I: Preparation of srnall unilaniellar CSPA-loaded vesicle.r from dioleoylphosphatid vlserine.
A mixture of dioleoylphosphatidylserine (DOPS) in chlorofonn (10 mg/ml) and CSPA in methanol (0.5mg/ml) at a molar ratio of 10:1 was placed in a round-bottom flask and dried to a fi]m using a Buchi rotavapor at room temperature. The rotavapor was sterilized by flashing nitrogen gas through a 0.2 m filter. The following steps were carried out in a sterile hood. The dried lipid film was hydrated with dc-ionized water at the concentration of 10 mg lipid/ml. The hydrated suspension was purged and sealed with nitrogen, then sonicated in a cooled bath sonicator. Sonication was continued (for several seconds to several minutes depending on lipid quantity and nature) until the suspension became clear (suspension A) and there were no liposomes apparently visible under a phase contrast microscope with a 1000X magnification.
Step 2 : Preparation of CSPA-loaded, hydrogel isolated, cochleates The liposome suspension obtained in step 1 was then mixed with 40 % w/w dextran-500,000 in a suspension of 2/1 v/v Dextran/liposome. This mixture was then injected via a syringe into 15 % w/w PEG-8,000 (Sigma) [PEG 8000/(suspension A)] under magnetic stirring to result in suspension B. The rate of the stirring was 800-1,000 rpnl. A CaCI2 solution (100 mM) was added to the suspension to reach the final concentration of ImM.
Stirring was continued for one hour, then a washing buffer containing 1 mM
CaC12 and 150 mM NaCI was addcd to suspension B at the volumetric ratio of 1: 1. The suspension was vortexed and centrifuged at 3000 rpm, 2-4 C, for 30 min. After the supernatant was removed, additional washing bufJer was added at the volunietric ratio of 0.5:1, followed by centrifugation under the same conditions. A scliematic of this new process of obtaining cochleates is detailed in Figure 1. The resultitig pellet was reconstituted with the same buffer to the desired concentration. Laser Iigllt scattering (weight analysis, Coulter N4 Plus) confirmed the formatiort of sniall CSPA-coclileates.
Example 7. Preparation of Nelfinavir (NV1R)loaded hydrogel isolated cochleates precipitated with calciuni Step 1: Preparation of small unilamellar NVIR-loaded vesicles from diole.oylphosPhatidyl,serine.
A mixture of diolcoylphosphatidylserine (DOPS) in chloroform (10 mg/ml) and NViR in methanol (0.5mg/ml) at a molar ratio of 10:1 was placed in a round-bottom flask and dried to a film using a Buchi rotavapor at RT. The rotavapor was sterilized by flashing nitrogen gas through a 0.2 m filter. The following steps were carried out in a sterile hood, The dried lipid film was hydrated with de-ionized water at the concentration of 10 mg lipid/ml. The hydrated suspension was purged and sealed with nitrogen, then sonicated in a cooled bath sonicalor. Sonication was continued (for several seconds to several minutes depending on lipid quantity and nature) until the suspension becanle clear (suspension A) and there were no liposonies apparentlv visible under a phase contrast microscope with a 1000X
magnification.
Step l: Preparation of NVIR-loadetl, Jrydrogel isolated, cochleates The liposome suspension obtained in stcp I was then niixed with 40 % w/w dextran-500,000 in a suspension of 2/1 v/v Dcxtran/liposome. This mixture was then injected via a syringe into 15 % w/w PEG-8,000 [PEG 8000/(suspension A)] undcr niagnetic stirring to result in suspension B. The rate of the stirring was 800-1,000 rpm. A CaC12 solution (100 mM) was added to the suspension to reach the final concentration of 1mM.
Stirring was continued for one hour, then a washing buffer containing 1 mM
CaCI2 and 150 mM NaCI was added to suspension B at the volumetric ratio of 1:1. The suspension was vortexed and centrifuged at 3000 rpm, 2-4 C, for 30 min. After the supernatant was removed, additional washing buffer was added at the volumetric ratio of 0.5:1, followed by centrifugation under the same conditions. A scheniatic of this new process of obtaining cochleates is detailed in Figure 1. 'I'he resulting pellet was reconstituted with the same buffer to the desired concentration. Laser light scattering (weight analysis, Coulter N4 Plus) confirmed the formatioii of small NV1R-cochleates.
Example 8. Preparation of Rifampin (RIF) -loaded hydrogel-isolated cocbleates precipitated with calciu[n Step 1: Preparation of small urtilaniellar RIF-loaded vesicles from dioleovlphosphatidyl serine.
A mixture of dioleoylphosphatidylscrine (DOPS) in chloroform (10 mg/ml) and RIF
in methanol (0.5mg/mi) at a molar ratio of 10:1 was plaeed in a round-bottom flask and dried to a film using a Buchi rotavapor at RT. The rotavapor was sterilized by flashing nitrogen gas through a 0.2 m filter. The following steps were carried out in a sterile hood. '1'he dried lipid film was hydrated with de-ionized water at the concentration of 10 mg lipid/ml. The hydrated suspension was purged and sealed with nitrogen, then sonicated in a cooled bath sonicator. Sonication was continued (for several seconds to several minutes depending on lipid quantity and nature) until the suspension became clear (suspension /1'i and there were no liposomes apparently visible under a phase contrast microscope with a 1000X
magnification.
Step 2: Preparation of RIF-loaded, hydrogel isolate, d cochleates The liposome suspension obtained in step I was then ntixed with 40 % w/w dextran-500,000 (Sigma) in a suspcnsion of 2/1 v/v Dcxtran/liposome. This mixture was then injected via a syringe into 15 % w/w PEG-8,000 (Sigma) [PFG 8000/(suspension A)] under magnetic stirring to result in suspension B. The rate of the stirring was 800-1,000 rpm. A
CaClz solution (100 mM) was added to the suspension to reach the final concentration of 1mM.
Stirring was continued for one hour, then a washing buffer containing 1 mM
CaC12 and 150 mM NaCl was added to suspension B at the volumetric ratio of 1:1. The suspension was vortexed and centrifuged at 3000 rpm, 2-4 C, for 30 min. After the supematant was removed, additional washing bufler was added at the volumetric ratio of 0.5:1, followed by centrifugation under the same conditions. A schematic of this new process of obtaining cochleates is detailed in Figure 1. The resulting pellet was reconstituted with the sacne buffer to the desired concentratioti. Laser light scattering (weight analysis, Coulter N4 Plus) eonfirmed the formation of small RIF-cochleates.
Claims (76)
1. A method for producing lipid-based cochleates comprising the steps of:
a) providing an aqueous suspension of liposomes;
b) mixing the liposome suspension with polymer A;
c) adding the liposome/polymer A suspension into a solution comprising polymer B, wherein polymer A and polymer B are immiscible, thereby creating a two-phase polymer system;
d) adding a solution of a cationic moiety to the two-phase polymer system; and e) washing the two-phase polymer system to remove the polymers.
a) providing an aqueous suspension of liposomes;
b) mixing the liposome suspension with polymer A;
c) adding the liposome/polymer A suspension into a solution comprising polymer B, wherein polymer A and polymer B are immiscible, thereby creating a two-phase polymer system;
d) adding a solution of a cationic moiety to the two-phase polymer system; and e) washing the two-phase polymer system to remove the polymers.
2. A method of claim 1 wherein the addition of liposome/polymer A suspension is done by injection.
3. A method of claim 1 or claim 2 wherein the liposomes are formed of lipid comprising negatively charged lipid.
4. A method of claim 3 wherein the negatively charged lipid is phosphatidylserine.
5. A method of claim 3 or claim 4 wherein the lipid comprises a minor amount of other lipids.
6. A method of claim 5 wherein the other lipid is selected from the group of zwitterionic lipids.
7. A method of claim 5 wherein the other lipid is selected from the group of cationic lipids.
8. A method of claim 5 wherein the other lipids are selected from the group of neutral lipids which form hydrogen bonds to a biologically active molecule.
9. A method of claim 8 wherein the neutral lipid is a PEGylated lipid.
10. A method of any one of claims 1 to 9 wherein polymer A is at least one member selected from the group consisting of dextran and polyethylene glycol.
11. A method of any one of claims 1 to 10 wherein the concentration of polymer A in the two-phase polymer system ranges in concentration from 2 to 20% w/w.
12. A method of any one of claims 1 to 11 wherein polymer B is at least one member selected from the group consisting of polyvinylpyrrolidone, polyvinylalcohol, Ficoll.TM., polyvinyl methyl ether, and polyethylene glycol.
13. A method of any one of claims 1 to 12 wherein the concentration of polymer B in the two-phase polymer system is the range of 2 to 20% w/w.
14. A method of any one of claims 1 to 13 wherein the two-phase polymer solution is at least one member selected from the group consisting of dextran/polyethylene glycol, dextran/polyvinylpyrrolidone, dextran/polyvinylalcohol, dextran/Ficoll.TM. and polyethylene glycol/polyvinyl methyl ether.
15. A method of any one of claims 1 to 14 wherein the cationic moiety comprises a di-or higher-valent ion.
16. A method of any one of claims 1 to 15 wherein the cationic moiety comprises a di-or higher-valent metal ion.
17. A method of claim 16 wherein the metal ion is added as a salt of an inorganic acid.
18. A method of any one of claims 1 to 17 wherein the lipid cochleates are small-sized cochleates.
19. A method according to claim 18 wherein the size of the cochleates is less than 1 micron.
20. A method according to claim 18 wherein the cochleates are formed using small unilamellar liposomes.
21. A method according to any one of claims 1 to 20 wherein the aqueous suspension of liposomes comprises a biologically relevant molecule, whereby the cochleates also comprise the biologically relevant molecule.
22. A method according to claim 21 which comprises the preliminary step of forming the liposome suspension by forming a film comprising a mixture of the biologically relevant molecule and lipid and contacting the film with an aqueous phase to form the aqueous suspension of small unilamellar liposomes.
23. A method according to claim 21 in which the biologically relevant molecule is present in the aqueous phase.
24. A method according to claim 23 comprising the preliminary step of forming liposomes in which a film of lipid is contacted with aqueous phase containing the biologically relevant molecule to form the aqueous suspension of liposomes.
25. A method according to claim 21 including a preliminary step in which a suspension of empty liposomes is mixed with the biologically relevant molecule to form the said liposome suspension.
26. A method according to claim 23 wherein the biologically relevant molecule bears a charge.
27. A method according to claim 26 wherein the biologically relevant molecule is positively charged.
28. A method according to claim 26 wherein the biologically relevant molecule is negatively charged.
29. A method according to claim 28 wherein the negatively charged molecule is a polynucleotide.
30. A method according to claim 29 wherein the polynucleotide is DNA.
31. A method for producing lipid-based cochleates comprising the steps of:
a) providing an aqueous suspension containing a detergent-lipid mixture;
b) mixing the detergent-lipid suspension with polymer A;
c) adding the detergent-lipid/polymer A suspension into a solution comprising polymer B, wherein polymer A and polymer B are immiscible, thereby creating a two-phase polymer system;
d) adding a solution of a cationic moiety to the two-phase polymer system; and e) washing the two-phase polymer system to remove the polymer.
a) providing an aqueous suspension containing a detergent-lipid mixture;
b) mixing the detergent-lipid suspension with polymer A;
c) adding the detergent-lipid/polymer A suspension into a solution comprising polymer B, wherein polymer A and polymer B are immiscible, thereby creating a two-phase polymer system;
d) adding a solution of a cationic moiety to the two-phase polymer system; and e) washing the two-phase polymer system to remove the polymer.
32. A method for producing lipid-based cochleates according to claim 31 wherein the detergent is octyl glucoside.
33. A method for producing lipid-based cochleates according to claim 31 wherein the cochleate comprises a biologically active molecule.
34. A method according to claim 33 wherein the biologically active molecule bears a charge.
35. A method according to claim 33 wherein the biologically active molecule is positively charged.
36. A method according to claim 33 wherein the biologically active molecule is negatively charged.
37. A method according to claim 36 wherein the negatively charged molecule is a polynucleotide.
38. A method according to claim 37 wherein the polynucleotide is DNA.
39. A method according to claim 33 wherein the biologically active molecule is added in step a.
40. A method according to claim 21 or claim 33 in which the biologically relevant molecule is selected from the group consisting of drugs, polynucleotides, polypeptides and antigens.
41. A method of claim 40 wherein the biologically relevant molecule is a drug selected from the group consisting of antiviral agents, anesthetics, anti-infectious agents, antibacterial agents, antifungal agents, anticancer agents, immunosuppressants, steroidal anti-inflammatory agents, non- steroidal anti-inflammatory agents, tranquilisers and vasodilators.
42. A method of claim 41 in which the drug is at least one member selected from the group consisting of Amphotericin B, acyclovir, adriamycin, cabamazepine, melphalan, nelfinavir, nifedipine, indomethacin, naproxen, estrogens, testosterones, steroids, phenytoin, ergotamines, cannabinoids rapamycin, propanidid, propofol, alphadione, echinomycin, miconazole nitrate, teniposide, taxol, taxotere and rifampin.
43. A method according to any one of claims 1 to 42 in which the washing step involved centrifuging the two-phase polymer system to separate the cochleate precipitate, removing the supernatant containing the polymer, resuspending the precipitate in a washing buffer, centrifuging the washed precipitate, and optionally repeating the resuspension and centrifugation steps one or more times.
44. A method according to claim 43 in which the washing buffer contains dissolved cationic moiety.
45. A method according to claim 44 in which the cationic moiety comprises di-or higher-valent ions.
46. A method according to claim 45 in which the di-or higher-valent ions are metal ions.
47. A method according to claim 46 in which the metal ions are selected from calcium and zinc.
48. A method according to any one of claims 43 to 47 in which the cationic moiety is present in the washing buffer at a concentration of at least 1mM.
49. A cochleate composition comprising:
a) a negatively charged lipid;
b) a cation component; and c) a biologically relevant molecule other than a) and b) wherein the cochleates have a mean particle size of less than 1 µm, and wherein said cation component is a di- or higher valent metal ion.
a) a negatively charged lipid;
b) a cation component; and c) a biologically relevant molecule other than a) and b) wherein the cochleates have a mean particle size of less than 1 µm, and wherein said cation component is a di- or higher valent metal ion.
50. A cochleate composition according to claim 49 in which the biologically relevant molecule is selected from vitamins, minerals, amino acids, toxins, microbicides, microbistats, co-factors, enzymes, polypeptides, polypeptide aggregates, polynucleotides, lipids, carbohydrates, nucleotides, starches, pigments, fatty acids, hormones, cytokines, viruses, organelles, steroids and other multi-ring structures, saccharides, metals, metabolic poisons and drugs.
51. A cochleate composition according to claim 50 wherein the biologically relevant molecule is a drug selected from the group consisting of antiviral agents, anesthetics, anti-infectious agents, antibacterial agents, antifungal agents, anticancer agents, immunosuppressants, steroidal anti-inflammatory agents, non-steriodal anti-inflammatory agents, tranquilisers and vasodilators.
52. A cochleate composition according to claim 51 wherein the drug is at least one member selected from the group consisting of Amphotericin B, acyclovir, adriamycin, cabamazepine, melphalan, nelfinavir, nifedipine, indomethacin, naproxen, estrogens, testosterones, steroids, phenytoin, ergotamines, cannabinoids rapamycin, propanidid, propofol, alphadione, echinomycin, miconazole nitrate, teniposide, taxol, taxotere and rifampin.
53. A cochleate composition according to claim 49 in which the biologically relevant molecule is Amphotericin B.
54. A cochleate composition according to claim 49 in which the biologically relevant molecule is naproxen.
55. A cochleate composition according to claim 49, in which the biologically relevant molecule is a polypeptide selected from cyclosporin, angiotensin I, II and III, enkephalins and their analogs, ACTH, anti-inflammatory peptides I, II and III, bradykinin, calcitonin, b-endorphin, dinorphin, leucokinin, leutinizing hormone releasing hormone (LHRH), insulin, neurokinins, somatostatin, substance P, thyroid releasing hormone (TRH) and vasopressin.
56. A cochleate composition according to claim 49 in which the biologically relevant molecule is an antigen.
57. A cochleate composition according to claim 56 wherein the antigen is a carbohydrate, a polynucleotide, or a protein.
58. A cochleate composition according to claim 57 wherein the protein antigen is selected from envelope glycoproteins from influenza or Sendai viruses, animal cell membrane proteins, plant cell membrane proteins, bacterial membrane proteins and parasitic membrane proteins.
59. A cochleate composition according to claim 49 in which the biologically relevant molecule is Vitamin A.
60. A cochleate composition according to claim 49 in which the biologically relevant molecule is polyunsaturated fatty acid.
61. A cochleate composition according to claim 49 in which the biologically relevant molecule is polynucleotide.
62. A cochleate composition according to claim 61 wherein the polynucleotide is DNA.
63. A cochleate composition according to claim 49 in which the metal ion is selected from calcium, magnesium, zinc and barium.
64. A cochleate composition according to claim 49 or 50 in which the negatively charged lipid is phosphatidylserine.
65. A cochleate composition according to claim 49 or 50 which comprises a further lipid in an amount less than 50% of an overall total of the cochleate composition, said further lipid selected from zwitterionic lipid, cationic lipid and neutral lipid.
66. A cochleate composition according to claim 65 wherein the further lipid is a neutral lipid which forms hydrogen bonds to the biologically relevant molecule.
67. A cochleate according to claim 66 wherein the further lipid is a PEGylated lipid.
68. Cochleate composition according to any one of claims 49-67, or the product of a method of any one of claims 1-48, for use in a method of delivering a biologically relevant molecule to a host.
69. Use of a cochleate composition according to any one of claims 49-67, or of the product of a method according to any one of claims 1-48, in the manufacture of a composition for use in a method of treatment of the human or animal body or to deliver a biologically relevant molecule to a host.
70. Use according to claim 69 in which the composition is suitable for mucosal or systemic administration.
71. Use of claim 70 wherein the composition is suitable for administration by a mucosal route selected from oral, intranasal, intraocular, intraanal, intravaginal, parenteral or intrapulmonary.
72. Use according to claim 71 in which the route is oral.
73. Use according to claim 71 in which the composition is an aerosol.
74. Use according to claim 70 wherein the composition is suitable for administration by a systemic route selected from intravenous, intramuscular, subcutaneous, transdermal or intradermal.
75. A pharmaceutical composition comprising a cochleate composition according to any one of claims 49-67 and a pharmaceutically acceptable carrier.
76. The method of claim 17 wherein the inorganic acid includes calcium chloride, zinc chloride or cobalt chloride.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/235,400 | 1999-01-22 | ||
| US09/235,400 US6153217A (en) | 1999-01-22 | 1999-01-22 | Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents |
| PCT/US2000/001684 WO2000042989A2 (en) | 1999-01-22 | 2000-01-24 | Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2358505A1 CA2358505A1 (en) | 2000-07-27 |
| CA2358505C true CA2358505C (en) | 2010-04-06 |
Family
ID=22885334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2358505A Expired - Fee Related CA2358505C (en) | 1999-01-22 | 2000-01-24 | Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US6153217A (en) |
| EP (1) | EP1143933B1 (en) |
| JP (1) | JP2002535267A (en) |
| AT (1) | ATE367800T1 (en) |
| AU (1) | AU3213300A (en) |
| CA (1) | CA2358505C (en) |
| CY (1) | CY1106916T1 (en) |
| DE (1) | DE60035669T2 (en) |
| DK (1) | DK1143933T3 (en) |
| ES (1) | ES2290019T3 (en) |
| PT (1) | PT1143933E (en) |
| WO (1) | WO2000042989A2 (en) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6153217A (en) | 1999-01-22 | 2000-11-28 | Biodelivery Sciences, Inc. | Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents |
| CA2397792A1 (en) * | 2000-01-24 | 2001-07-26 | Biodelivery Sciences, Inc. | Cochleate formulations and their use for delivering biologically relevant molecules |
| DE10154464B4 (en) * | 2001-11-08 | 2005-10-20 | Max Delbrueck Centrum | Orally administrable pharmaceutical preparation comprising liposomally encapsulated taxol |
| US20030219473A1 (en) * | 2002-03-26 | 2003-11-27 | Leila Zarif | Cochleates made with purified soy phosphatidylserine |
| US20040092727A1 (en) * | 2002-11-13 | 2004-05-13 | Biopharm Solutions Inc. | Cochleates without metal cations as bridging agents |
| WO2004012709A1 (en) * | 2002-08-06 | 2004-02-12 | Tuo Jin | Cochleates without metal cations as the bridging agents |
| JP3927887B2 (en) * | 2002-08-09 | 2007-06-13 | 本田技研工業株式会社 | Stator blade of axial compressor |
| US8685428B2 (en) * | 2002-12-10 | 2014-04-01 | Advanced Cardiovascular Systems, Inc. | Therapeutic composition and a method of coating implantable medical devices |
| US8980310B2 (en) * | 2002-12-31 | 2015-03-17 | Bharat Serums and Vaccines, Ltd. | Non-pegylated long-circulating liposomes |
| US20050008686A1 (en) * | 2003-01-15 | 2005-01-13 | Mannino Raphael J. | Cochleate preparations of fragile nutrients |
| EP1631669A2 (en) * | 2003-04-09 | 2006-03-08 | Biodelivery Sciences International, Inc. | Cochleate compositions directed against expression of proteins |
| WO2004091578A2 (en) | 2003-04-09 | 2004-10-28 | Biodelivery Sciences International, Inc. | Novel encochleation methods, cochleates and methods of use |
| DE10322439A1 (en) * | 2003-05-19 | 2004-12-09 | Bayer Ag | Method and device for determining the isomer composition in isocyanate production processes |
| SE527505C2 (en) * | 2003-06-10 | 2006-03-28 | Anna Imberg | Composite materials and particles |
| US20060188573A1 (en) * | 2003-06-10 | 2006-08-24 | Anna Imberg | Composite materials and particles |
| WO2005037267A1 (en) * | 2003-10-15 | 2005-04-28 | Ltt Bio-Pharma Co., Ltd. | Method of controlling paticle size of retinoic acid nanoparticles coated with polyvalent metal inorganic salt and nanoparticles obtained by the controlling method |
| EP1674094A4 (en) * | 2003-10-15 | 2009-12-09 | Nanoegg Res Lab Inc | Composition containing retinoic acid nanoparticles coated with polyvalent metal inorganic salt |
| WO2005063213A1 (en) * | 2003-12-19 | 2005-07-14 | Biodelivery Sciences International, Inc. | Rigid liposomal cochleate and methods of use and manufacture |
| US20050244522A1 (en) * | 2004-04-30 | 2005-11-03 | Carrara Dario Norberto R | Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents |
| US7494526B2 (en) * | 2004-07-14 | 2009-02-24 | Yavitz Edward Q | Plant protection and growth stimulation by nanoscalar particle folial delivery |
| US20060040896A1 (en) * | 2004-08-18 | 2006-02-23 | Paringenix, Inc. | Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity |
| US20070082107A1 (en) * | 2005-10-07 | 2007-04-12 | Aimutis William R Jr | Compositions and methods for reducing food intake and controlling weight |
| US20070082115A1 (en) * | 2005-10-07 | 2007-04-12 | Aimutis William Ronald Jr | Methods for inducing satiety, reducing food intake and reducing weight |
| US20070082030A1 (en) * | 2005-10-07 | 2007-04-12 | Aimutis William R | Fiber satiety compositions |
| US20070082029A1 (en) * | 2005-10-07 | 2007-04-12 | Aimutis William R | Fiber satiety compositions |
| US20100178325A1 (en) * | 2006-08-23 | 2010-07-15 | Biodelivery Sciences International, Inc. | Amphiphilic nucleotide cochleate compositions and methods of using the same |
| US20080085354A1 (en) * | 2006-10-06 | 2008-04-10 | Teresa Marie Paeschke | Controlled hydration of hydrocolloids |
| US20080220028A1 (en) * | 2006-12-15 | 2008-09-11 | National Research Council Of Canada | Archaeal polar lipid aggregates for administration to animals |
| US20090054374A1 (en) * | 2007-02-28 | 2009-02-26 | Paringenix, Inc. | Methods of treating acute exacerbations of chronic obstructive pulmonary disease |
| US8591225B2 (en) * | 2008-12-12 | 2013-11-26 | Align Technology, Inc. | Tooth movement measurement by automatic impression matching |
| US20090036405A1 (en) * | 2007-07-23 | 2009-02-05 | University Of Utah | Method for blocking ligation of the receptor for advanced glycation end-products (rage) |
| US20090047336A1 (en) * | 2007-08-17 | 2009-02-19 | Hong Kong Baptist University | novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation |
| JP2010539245A (en) | 2007-09-14 | 2010-12-16 | 日東電工株式会社 | Drug carrier |
| US8877242B2 (en) | 2008-07-14 | 2014-11-04 | Polypid Ltd. | Sustained-release drug carrier composition |
| US20100113352A1 (en) | 2008-11-06 | 2010-05-06 | Elliott Millstein | Retinol formulations and methods for their use |
| IN2012DN00570A (en) | 2009-07-14 | 2015-06-12 | Polypid Ltd | |
| WO2011016043A2 (en) | 2009-08-06 | 2011-02-10 | Technion Research & Development Foundation Ltd. | Antibiotic drug delivery and potentiation |
| WO2011031018A2 (en) * | 2009-09-14 | 2011-03-17 | 한남대학교 산학협력단 | Water-soluble drug delivery system allowing slow release |
| CN102892406B (en) * | 2010-01-19 | 2015-04-08 | 波利皮得有限公司 | Sustained-release nucleic acid matrix compositions |
| BR112012020089A2 (en) * | 2010-02-10 | 2016-05-17 | Biopelle Inc | retinol formulations and methods for using them |
| KR20230006042A (en) | 2011-04-29 | 2023-01-10 | 셀렉타 바이오사이언시즈, 인크. | Tolerogenic synthetic nanocarriers to reduce antibody responses |
| US20140220108A1 (en) * | 2011-05-05 | 2014-08-07 | University Of Medicine And Dentistry Of New Jersey | Cochleate compositions and methods of making and using same |
| EP2729569B1 (en) | 2011-07-06 | 2019-12-11 | The Regents of The University of California | Multiple-enzyme nanocomplexes |
| US9993440B2 (en) | 2011-09-02 | 2018-06-12 | The Regents Of The University Of California | Enzyme responsive nanocapsules for protein delivery |
| HUE053247T2 (en) | 2012-05-09 | 2021-06-28 | Cantex Pharmaceuticals Inc | Treatment of myelosuppression |
| US10973266B2 (en) * | 2013-03-15 | 2021-04-13 | Robert Bosch Tool Corporation | Heated garment and battery holster |
| CN110841067A (en) * | 2013-05-03 | 2020-02-28 | 西莱克塔生物科技公司 | Tolerogenic synthetic nanocarriers and therapeutic macromolecules for reduced or enhanced pharmacodynamic effects |
| US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9744239B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US10052346B2 (en) | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
| KR20180004104A (en) | 2015-03-03 | 2018-01-10 | 마티나스 바이오파마 나노테크놀로지스, 인코포레이티드 | Methods of using it to enhance tissue penetration of the coccales and pharmacologically active agents |
| SG11201803915UA (en) * | 2015-11-10 | 2018-06-28 | Childrens Research Institute Childrens National Medical Center | Echinomycin formulation, method of making and method of use thereof |
| AU2017297402B2 (en) * | 2016-07-12 | 2023-02-09 | Matinas Biopharma Nanotechnologies, Inc. | Encochleated antifungal compounds for central nervous system delivery and treatment of Cryptococcus infections |
| KR101989789B1 (en) | 2017-11-30 | 2019-06-18 | (주) 에이치엔에이파마켐 | Cochleates using phosphatidylserine/anionic surfactant/calcium chloride |
| JP6929471B2 (en) * | 2018-09-28 | 2021-09-01 | 株式会社マンダム | Cosmetics |
| EP4277654A1 (en) | 2021-01-18 | 2023-11-22 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
| WO2024039733A1 (en) | 2022-08-16 | 2024-02-22 | Matinas Biopharma Nanotechnologies, Inc. | Methods of controlling lipid nanocrystal particle size and lipid nanocrystals produced by such methods |
| WO2024039729A1 (en) | 2022-08-16 | 2024-02-22 | Matinas Biopharma Nanotechnologies, Inc. | Antifungal agent encapsulated in a lipid nanocrystal for treating mucormycosis |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663161A (en) * | 1985-04-22 | 1987-05-05 | Mannino Raphael J | Liposome methods and compositions |
| US4871488A (en) * | 1985-04-22 | 1989-10-03 | Albany Medical College Of Union University | Reconstituting viral glycoproteins into large phospholipid vesicles |
| US4990291A (en) * | 1986-04-15 | 1991-02-05 | The United States Of America As Represented By The Secretary Of The Navy | Method of making lipid tubules by a cooling process |
| US5269979A (en) * | 1988-06-08 | 1993-12-14 | Fountain Pharmaceuticals, Inc. | Method for making solvent dilution microcarriers |
| JP2880800B2 (en) * | 1989-06-22 | 1999-04-12 | ネクスター・フアーマシユーテイカルズ・インコーポレイテツド | Encapsulation method |
| US5840707A (en) * | 1993-10-04 | 1998-11-24 | Albany Medical College | Stabilizing and delivery means of biological molecules |
| US5643574A (en) * | 1993-10-04 | 1997-07-01 | Albany Medical College | Protein- or peptide-cochleate vaccines and methods of immunizing using the same |
| US5994318A (en) * | 1993-10-04 | 1999-11-30 | Albany Medical College | Cochleate delivery vehicles |
| CA2246754C (en) | 1996-02-22 | 2002-10-22 | Raphael James Mannino | Cochleate delivery vehicles |
| US6120751A (en) * | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6153217A (en) | 1999-01-22 | 2000-11-28 | Biodelivery Sciences, Inc. | Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents |
-
1999
- 1999-01-22 US US09/235,400 patent/US6153217A/en not_active Expired - Fee Related
-
2000
- 2000-01-24 DE DE60035669T patent/DE60035669T2/en not_active Expired - Lifetime
- 2000-01-24 DK DK00909961T patent/DK1143933T3/en active
- 2000-01-24 AU AU32133/00A patent/AU3213300A/en not_active Abandoned
- 2000-01-24 ES ES00909961T patent/ES2290019T3/en not_active Expired - Lifetime
- 2000-01-24 CA CA2358505A patent/CA2358505C/en not_active Expired - Fee Related
- 2000-01-24 EP EP00909961A patent/EP1143933B1/en not_active Expired - Lifetime
- 2000-01-24 AT AT00909961T patent/ATE367800T1/en active
- 2000-01-24 JP JP2000594446A patent/JP2002535267A/en active Pending
- 2000-01-24 PT PT00909961T patent/PT1143933E/en unknown
- 2000-01-24 WO PCT/US2000/001684 patent/WO2000042989A2/en active IP Right Grant
- 2000-07-11 US US09/613,840 patent/US6592894B1/en not_active Expired - Lifetime
-
2003
- 2003-04-23 US US10/421,358 patent/US20030228355A1/en not_active Abandoned
-
2005
- 2005-01-18 US US11/040,615 patent/US20050186265A1/en not_active Abandoned
-
2007
- 2007-10-08 CY CY20071101285T patent/CY1106916T1/en unknown
-
2008
- 2008-04-23 US US12/148,942 patent/US20090028904A1/en not_active Abandoned
-
2012
- 2012-04-06 US US13/441,030 patent/US20120294901A1/en not_active Abandoned
-
2013
- 2013-12-31 US US14/145,268 patent/US20140220109A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2290019T3 (en) | 2008-02-16 |
| ATE367800T1 (en) | 2007-08-15 |
| EP1143933B1 (en) | 2007-07-25 |
| AU3213300A (en) | 2000-08-07 |
| US20030228355A1 (en) | 2003-12-11 |
| US6592894B1 (en) | 2003-07-15 |
| US20050186265A1 (en) | 2005-08-25 |
| CY1106916T1 (en) | 2012-09-26 |
| WO2000042989A2 (en) | 2000-07-27 |
| US6153217A (en) | 2000-11-28 |
| DE60035669D1 (en) | 2007-09-06 |
| DK1143933T3 (en) | 2007-11-26 |
| DE60035669T2 (en) | 2008-02-07 |
| US20140220109A1 (en) | 2014-08-07 |
| PT1143933E (en) | 2007-09-03 |
| EP1143933A2 (en) | 2001-10-17 |
| JP2002535267A (en) | 2002-10-22 |
| US20090028904A1 (en) | 2009-01-29 |
| US20120294901A1 (en) | 2012-11-22 |
| WO2000042989A3 (en) | 2000-11-30 |
| CA2358505A1 (en) | 2000-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2358505C (en) | Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules | |
| Jadhav et al. | Novel vesicular system: an overview | |
| RU2493874C2 (en) | Transpulmonary liposome for controlling drug delivery | |
| US20030235619A1 (en) | Polymer-lipid delivery vehicles | |
| US20060177495A1 (en) | Polymer-lipid delivery vehicles | |
| US20030219473A1 (en) | Cochleates made with purified soy phosphatidylserine | |
| EP1759699B1 (en) | Liposome preparation containing slightly water-soluble camptothecin | |
| Spitler et al. | Drug delivery systems: possibilities and challenges | |
| Mbah et al. | Vesicular carriers as innovative nanodrug delivery formulations | |
| AU3111401A (en) | New cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules | |
| Hasan et al. | Liposomes: An advance tools for novel drug delivery system | |
| Gol et al. | Nanocochleates: A novel approach for drug delivery | |
| US20040092727A1 (en) | Cochleates without metal cations as bridging agents | |
| Shivhare et al. | A Review on Liposomes as a Novel Drug Delivery System | |
| WO2004012709A1 (en) | Cochleates without metal cations as the bridging agents | |
| WO2018124423A1 (en) | Polymer nanoparticle composition for plasmid dna delivery, and preparation method therefor | |
| Rushikesh et al. | The Liposome Revolution: Advances and Applications in Drug Delivery | |
| Gregory | Preparation of Liposomes and Oily Formulations by Freeze-Drying of Monophase Solutions | |
| Li et al. | Preparation of liposomes and oily formulations by freeze-drying of monophase solutions | |
| AU2007200813B2 (en) | Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules | |
| AU2004200967A1 (en) | Novel hydrogel isolated ochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules | |
| Gregoriadis | Preparation of Liposomes and Oily Formulations by Freeze-Drying of Monophase Solutions.............. ChunLei Li, YingJie Deng, and JingXia Cui | |
| AU2006202639A1 (en) | New cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules | |
| Sangeetha et al. | Research Journal of Pharmaceutical, Biological and Chemical Sciences | |
| WO2013015674A1 (en) | Collagen nanostructures |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20130124 |